1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pluristem Therapeutics Inc. - Product Pipeline Review - 2015

Pluristem Therapeutics Inc. - Product Pipeline Review - 2015

  • November 2015
  • -
  • Global Markets Direct
  • -
  • 33 pages

Pluristem Therapeutics Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Pluristem Therapeutics Inc. - Product Pipeline Review - 2015’, provides an overview of the Pluristem Therapeutics Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pluristem Therapeutics Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pluristem Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pluristem Therapeutics Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pluristem Therapeutics Inc.’s pipeline products

Reasons to buy

- Evaluate Pluristem Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pluristem Therapeutics Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pluristem Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pluristem Therapeutics Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pluristem Therapeutics Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Pluristem Therapeutics Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Pluristem Therapeutics Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Pluristem Therapeutics Inc. Snapshot 4
Pluristem Therapeutics Inc. Overview 4
Key Information 4
Key Facts 4
Pluristem Therapeutics Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Pluristem Therapeutics Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pluristem Therapeutics Inc. - Pipeline Products Glance 9
Pluristem Therapeutics Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Pluristem Therapeutics Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Pluristem Therapeutics Inc. - Drug Profiles 12
PLX-PAD 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
PLXR-18 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Stem Cell Therapy for Inflammatory Bowel Disease 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Pluristem Therapeutics Inc. - Pipeline Analysis 20
Pluristem Therapeutics Inc. - Pipeline Products by Route of Administration 20
Pluristem Therapeutics Inc. - Pipeline Products by Molecule Type 21
Pluristem Therapeutics Inc. - Recent Pipeline Updates 22
Pluristem Therapeutics Inc. - Dormant Projects 30
Pluristem Therapeutics Inc. - Locations And Subsidiaries 31
Head Office 31
Other Locations and Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Pluristem Therapeutics Inc., Key Information 4
Pluristem Therapeutics Inc., Key Facts 4
Pluristem Therapeutics Inc. - Pipeline by Indication, 2015 6
Pluristem Therapeutics Inc. - Pipeline by Stage of Development, 2015 7
Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, 2015 8
Pluristem Therapeutics Inc. - Phase II, 2015 9
Pluristem Therapeutics Inc. - Phase I, 2015 10
Pluristem Therapeutics Inc. - Preclinical, 2015 11
Pluristem Therapeutics Inc. - Pipeline by Route of Administration, 2015 20
Pluristem Therapeutics Inc. - Pipeline by Molecule Type, 2015 21
Pluristem Therapeutics Inc. - Recent Pipeline Updates, 2015 22
Pluristem Therapeutics Inc. - Dormant Developmental Projects,2015 30
Pluristem Therapeutics Inc., Subsidiaries 31

List of Figures
Pluristem Therapeutics Inc. - Pipeline by Top 10 Indication, 2015 6
Pluristem Therapeutics Inc. - Pipeline by Stage of Development, 2015 7
Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, 2015 8
Pluristem Therapeutics Inc. - Pipeline by Top 10 Route of Administration, 2015 20
Pluristem Therapeutics Inc. - Pipeline by Top 10 Molecule Type, 2015 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Toxoplasmosis - Pipeline Review, H1 2016

Toxoplasmosis - Pipeline Review, H1 2016

  • $ 42 529
  • Company report
  • June 2016
  • by Global Markets Direct

Toxoplasmosis - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Toxoplasmosis - Pipeline Review, H1 2016’, provides an overview of the Toxoplasmosis pipeline landscape. The report provides ...

Encephalopathy - Pipeline Review, H1 2016

Encephalopathy - Pipeline Review, H1 2016

  • $ 42 529
  • Company report
  • June 2016
  • by Global Markets Direct

Encephalopathy - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Encephalopathy - Pipeline Review, H1 2016’, provides an overview of the Encephalopathy pipeline landscape. The report provides ...

Poliomyelitis - Pipeline Review, H1 2016

Poliomyelitis - Pipeline Review, H1 2016

  • $ 42 529
  • Company report
  • June 2016
  • by Global Markets Direct

Poliomyelitis - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Poliomyelitis - Pipeline Review, H1 2016’, provides an overview of the Poliomyelitis pipeline landscape. The report provides ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.